[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Koga F, Kawano K, Honda M, Sumi S, Horimi H, Kondo S, Yoshida K: Sarcomatoid renal cell carcinoma with scant carcinomatous components. Int J Urol; 2000 Feb;7(2):58-60; discussion 61
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid renal cell carcinoma with scant carcinomatous components.
  • A 30-year-old male underwent radical nephrectomy for a right renal tumor 15 cm in diameter.
  • At that time a diagnosis of rhabdomyosarcoma of the kidney was made.
  • However, further microscopic examination of another eight sections revealed small areas of clear cell-type renal cell carcinoma (RCC) which transited to sarcomatous components and led to a diagnosis of sarcomatoid RCC.
  • The patient underwent three cycles of adjuvant chemotherapy.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10710249.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] AUSTRALIA
  •  go-up   go-down


2. Taniguchi E, Nishijo K, McCleish AT, Michalek JE, Grayson MH, Infante AJ, Abboud HE, Legallo RD, Qualman SJ, Rubin BP, Keller C: PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene; 2008 Nov 20;27(51):6550-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma.
  • Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood.
  • Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis.
  • These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 2000 Mar;57(3):908-17 [10720944.001]
  • [Cites] FEBS Lett. 2007 Dec 22;581(30):5831-5 [18053811.001]
  • [Cites] J Exp Med. 2001 Sep 3;194(5):581-9 [11535627.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Genes Dev. 2002 Mar 15;16(6):676-80 [11914272.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):251-65 [12001987.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • [Cites] N Engl J Med. 2003 Mar 27;348(13):1201-14 [12660384.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):660-9 [15098008.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Feb;80(3):731-5 [6298772.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4118-30 [9632796.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Physiol Rev. 1999 Oct;79(4):1283-316 [10508235.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] J Cell Biochem. 2004 Nov 1;93(4):741-52 [15660418.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3206-13 [16030188.001]
  • [Cites] Curr Biol. 2005 Oct 25;15(20):1861-6 [16243034.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):329-38 [16261596.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2060-9 [16331269.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 23;103(21):8078-83 [16690743.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Cancer. 2007 Nov 15;110(10):2293-303 [17896786.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):55-61 [11333300.001]
  • (PMID = 18679424.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30CA54174; United States / NCI NIH HHS / CA / R01 CA133229; United States / NCI NIH HHS / CA / CA133229-01; United States / NCI NIH HHS / CA / P30 CA054174; United States / NCI NIH HHS / CA / R01 CA133229-01; United States / NCI NIH HHS / CA / R01CA133229
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha
  • [Other-IDs] NLM/ NIHMS161083; NLM/ PMC2813858
  •  go-up   go-down


3. Yoshimura N, Kanda H, Suzuki R, Yamakawa K, Hayashi N, Arima K, Yanagawa M, Kawamura J: [Cyclophosphamide-induced renal pelvic tumor--a case report]. Hinyokika Kiyo; 2000 Mar;46(3):177-80
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cyclophosphamide-induced renal pelvic tumor--a case report].
  • We report a case of transitional cell carcinoma in the left renal pelvis, which occurred in a 24-year-old man.
  • He had been treated with cyclophosphamide (CPM) for a period of 27 months for retroperitoneal rhabdomyosarcoma diagnosed at the age of 10.
  • Drip infusion pyelography revealed a filling defect in the left renal pelvis.
  • A left renal pelvic tumor was strongly suspected on computerized tomography and magnetic resonance imaging.
  • Histological diagnosis of the left renal pelvic tumor was transitional cell carcinoma, grade 2, pT1N0M0.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carcinoma, Transitional Cell / chemically induced. Cyclophosphamide / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Neoplasms / chemically induced. Neoplasms, Second Primary / etiology
  • [MeSH-minor] Adult. Humans. Kidney Pelvis. Male. Nephrectomy. Retroperitoneal Neoplasms / drug therapy. Rhabdomyosarcoma / drug therapy. Time Factors. Treatment Outcome. Ureter / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10806575.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 12
  •  go-up   go-down


Advertisement
4. Yu Y, Lee P, Ke Y, Zhang Y, Yu Q, Lee J, Li M, Song J, Chen J, Dai J, Do Couto FJ, An Z, Zhu W, Yu GL: A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models. PLoS One; 2010;5(2):e9072
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Though these properties are also highly desirable for therapeutic applications, rabbit antibodies have remained untapped for human disease therapy.
  • To evaluate the therapeutic potential of rabbit monoclonal antibodies (RabMAbs), we generated a panel of neutralizing RabMAbs against human vascular endothelial growth factor-A (VEGF).
  • We showed that the humanized RabMAb retained its parental biological properties and showed potent inhibition of the growth of H460 lung carcinoma and A673 rhabdomyosarcoma xenografts in mice.
  • These studies provide proof of principle for the feasibility of developing humanized RabMAbs as therapeutics.
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibody Affinity / immunology. Antibody Specificity / immunology. Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Epitope Mapping. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Molecular Sequence Data. Phosphorylation / drug effects. Rabbits. Sequence Homology, Amino Acid. Tumor Burden / drug effects. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Protoc. 2007;2(11):3001-8 [18007636.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1134-43 [17921999.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2666-76 [18160686.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1774-7 [18398141.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7192-7 [9207067.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3717-21 [10572084.001]
  • [Cites] Cancer. 2000 May 15;88(10):2239-45 [10820344.001]
  • [Cites] Hybridoma. 2000 Jun;19(3):201-14 [10952409.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6253-8 [11103779.001]
  • [Cites] J Mol Biol. 2003 Jan 10;325(2):325-35 [12488098.001]
  • [Cites] Leukemia. 2003 Mar;17(3):604-11 [12646950.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43496-507 [12917408.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Nature. 1984 Sep 6-11;311(5981):74-6 [6433207.001]
  • [Cites] Hybridoma. 1982;1(4):465-72 [6208141.001]
  • [Cites] Nature. 1986 May 29-Jun 4;321(6069):522-5 [3713831.001]
  • [Cites] Development. 1987 Jun;100(2):351-63 [3308402.001]
  • [Cites] EMBO J. 1989 Dec 1;8(12):3733-9 [2511000.001]
  • [Cites] Protein Eng. 1991 Oct;4(7):773-83 [1798701.001]
  • [Cites] Anal Biochem. 1991 Nov 1;198(2):268-77 [1724720.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 16;84(24):1875-87 [1281237.001]
  • [Cites] Proteins. 1993 May;16(1):1-7 [8497480.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):969-73 [8302875.001]
  • [Cites] Mol Immunol. 1994 Feb;31(3):169-217 [8114766.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9348-52 [7568130.001]
  • [Cites] Structure. 1997 Oct 15;5(10):1325-38 [9351807.001]
  • [Cites] J Mol Biol. 1997 Nov 7;273(4):927-48 [9367782.001]
  • [Cites] J Biol Chem. 1998 Jan 30;273(5):3033-8 [9446618.001]
  • [Cites] Mol Biol Evol. 1998 Jun;15(6):617-25 [9615443.001]
  • [Cites] Br J Cancer. 1998 Aug;78(4):478-83 [9716030.001]
  • [Cites] Structure. 1998 Sep 15;6(9):1153-67 [9753694.001]
  • [Cites] Cancer Metastasis Rev. 1998 Jun;17(2):155-61 [9770111.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Nov 27;252(3):643-8 [9837760.001]
  • [Cites] Oncogene. 1999 Feb 25;18(8):1619-27 [10102632.001]
  • [Cites] Nucleic Acids Res. 2005 Jan 1;33(Database issue):D671-4 [15608286.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):792-9 [15681523.001]
  • [Cites] Methods. 2005 May;36(1):3-10 [15848070.001]
  • [Cites] Am J Clin Pathol. 2005 Aug;124(2):295-302 [16040303.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1105-16 [16151404.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1117-25 [16151405.001]
  • [Cites] Anal Biochem. 2005 Dec 1;347(1):159-61 [16229811.001]
  • [Cites] Exp Cell Res. 2006 Feb 15;312(4):411-22 [16343483.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):951-61 [16278208.001]
  • [Cites] J Biol Chem. 2006 Mar 10;281(10):6625-31 [16373345.001]
  • [Cites] Nat Rev Immunol. 2006 May;6(5):343-57 [16622479.001]
  • [Cites] JAMA. 2006 May 17;295(19):2275-85 [16705109.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):229-33 [16785796.001]
  • [Cites] Am J Kidney Dis. 2007 Feb;49(2):186-93 [17261421.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):349-56 [17431406.001]
  • [Cites] Bioinformatics. 2007 Nov 1;23(21):2947-8 [17846036.001]
  • (PMID = 20140208.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  • [Other-IDs] NLM/ PMC2816707
  •  go-up   go-down


5. Okamoto M, Nako Y, Tachibana A, Fujiu T, Ohki Y, Tomomasa T, Morikawa A: Efficacy of phenytoin against hyponatremic seizures due to SIADH after administration of anticancer drugs in a neonate. J Perinatol; 2002 Apr-May;22(3):247-8
Hazardous Substances Data Bank. PHENYTOIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of phenytoin against hyponatremic seizures due to SIADH after administration of anticancer drugs in a neonate.
  • A neonate with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) developed refractory hyponatremic seizures following administration of anticancer drugs.
  • The low water-excretion capacity in neonates should be taken into consideration when fluid loading is attempted, to avoid renal damage upon administration of drugs such as cisplatin that have a potential damaging effect on the kidney.
  • Phenytoin could be the therapy of choice for SIADH and resulting seizures in the neonatal period.
  • [MeSH-major] Anticonvulsants / adverse effects. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Hyponatremia / etiology. Inappropriate ADH Syndrome / chemically induced. Orbital Neoplasms / drug therapy. Phenytoin / adverse effects. Rhabdomyosarcoma / drug therapy. Seizures / drug therapy

  • Genetic Alliance. consumer health - Seizures.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948390.001).
  • [ISSN] 0743-8346
  • [Journal-full-title] Journal of perinatology : official journal of the California Perinatal Association
  • [ISO-abbreviation] J Perinatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 6158TKW0C5 / Phenytoin
  •  go-up   go-down


6. Skinner R, Cotterill SJ, Stevens MC: Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br J Cancer; 2000 May;82(10):1636-45
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.
  • The aim of this multicentre study was to document the nephrotoxicity associated with ifosfamide and evaluate risk factors in 148 children and young people with sarcomas who underwent investigation of renal function on one occasion each, at a median of 6 (range 1-47) months after completion of ifosfamide (median dose 62.0 (range 6.1-165.0) g/m2).
  • Investigations included glomerular filtration rate (GFR), serum bicarbonate (HCO3) and phosphate (PO4), and renal tubular threshold for phosphate (Tmp/GFR).
  • Higher total ifosfamide dose correlated significantly with greater glomerular and tubular toxicity (P < 0.01); other risk factors, including age at treatment, demonstrated no consistent significant independent effect.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Ifosfamide / adverse effects. Kidney / drug effects
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / drug therapy. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Infant. Kidney Glomerulus / drug effects. Kidney Tubules / drug effects. Male. Neuroectodermal Tumors, Primitive / drug therapy. Prospective Studies. Regression Analysis. Rhabdomyosarcoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Dis Child. 1970 Aug;45(242):496-501 [5472688.001]
  • [Cites] Cancer Chemother Rep. 1974 Nov-Dec;58(6):889-93 [4614898.001]
  • [Cites] Pediatrics. 1965 Apr;35:601-19 [14269712.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3628-33 [9817284.001]
  • [Cites] Br Med Bull. 1996 Oct;52(4):898-923 [9039739.001]
  • [Cites] Med Pediatr Oncol. 1997 Jan;28(1):62-4 [8950339.001]
  • [Cites] Lancet. 1996 Aug 31;348(9027):578-80 [8774570.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1179-84 [8758250.001]
  • [Cites] Med Pediatr Oncol. 1996 Sep;27(3):149-55 [8699991.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1994 Nov;16(4):286-95 [7978043.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(5):431-3 [8070011.001]
  • [Cites] Eur J Pediatr. 1994 Feb;153(2):90-4 [8157032.001]
  • [Cites] J Clin Oncol. 1994 Jan;12(1):159-65 [8270973.001]
  • [Cites] Acta Paediatr. 1993 Apr;82(4):373-6 [8318805.001]
  • [Cites] Clin Nephrol. 1982 Apr;17(4):163-71 [7075034.001]
  • [Cites] Semin Oncol. 1982 Dec;9(4 Suppl 1):78-86 [6298946.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Mar;20(3):435-6 [6423391.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):28-34 [3510280.001]
  • [Cites] Cancer Chemother Pharmacol. 1986;18 Suppl 2:S18 [3102090.001]
  • [Cites] J Natl Cancer Inst. 1988 Jun 15;80(8):556-66 [3286879.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 May;24(5):903-8 [3169095.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;23(2):121-2 [2910509.001]
  • [Cites] Clin Nephrol. 1988 Oct;30(4):225-9 [3214967.001]
  • [Cites] Eur J Pediatr. 1988 Nov;148(2):164-6 [3234441.001]
  • [Cites] Lancet. 1989 Jul 8;2(8654):103-4 [2567844.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24 Suppl 1:S24-7 [2503257.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24 Suppl 1:S45-7 [2667789.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24 Suppl 1:S8-10 [2503259.001]
  • [Cites] Lancet. 1990 Apr 28;335(8696):1022-3 [1970073.001]
  • [Cites] J Pediatr. 1990 Aug;117(2 Pt 1):331-5 [2166154.001]
  • [Cites] Arch Dis Child. 1990 Jul;65(7):732-8 [2386379.001]
  • [Cites] CA Cancer J Clin. 1990 Nov-Dec;40(6):355-67 [2121321.001]
  • [Cites] J Pediatr. 1991 Feb;118(2):325-6 [1993970.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1991 Spring;13(1):39-41 [2029077.001]
  • [Cites] Cancer Chemother Pharmacol. 1991;28(2):81-92 [2060086.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1495-9 [1649270.001]
  • [Cites] J Clin Oncol. 1991 Dec;9(12):2177-82 [1720453.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):42-7 [1727210.001]
  • [Cites] Pediatr Nephrol. 1992 Mar;6(2):162-5 [1571213.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):254-7 [1574040.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):173-90 [8418231.001]
  • (PMID = 10817497.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC2374517
  •  go-up   go-down


7. Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J Jr: Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res; 2009 Jan 15;69(2):416-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nutlin-3 is a MDM2 inhibitor under preclinical investigation as nongenotoxic activator of the p53 pathway for cancer therapy.
  • Here, nutlin-3 was evaluated for its activity alone or in combination with established chemotherapeutic drugs for antitumor action in chemosensitive and chemoresistant neuroblastoma and rhabdomyosarcoma cell lines.
  • Effects of nutlin-3 single treatment were much more pronounced in p53 wild-type cell lines (IC(50)s <3 micromol/L) than in p53-mutated cell lines (IC(50)s >17 micromol/L).
  • Investigation of Madin-Darby canine kidney (MDCK) II cells stably transfected with plasmids encoding for P-gp (MDCKII MDR1) or multidrug resistance protein 1 (MRP-1, MDCKII MRP1) revealed that nutlin-3 not only interferes with P-gp but also affects MRP-1-mediated efflux.
  • Examination of the nutlin-3 enantiomers nutlin-3a and nutlin-3b revealed that, in contrast to MDM2-inhibitory activity that is limited to nutlin-3a, both enantiomers similarly interfere with P-gp-mediated drug efflux.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Imidazoles / pharmacology. Neuroblastoma / drug therapy. P-Glycoprotein / antagonists & inhibitors. Piperazines / pharmacology. Rhabdomyosarcoma, Alveolar / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Resistance, Neoplasm. Drug Synergism. Humans. Mice. Mutation. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Rhodamine 123 / pharmacokinetics. Stereoisomerism. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Protein p53 / genetics. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19147553.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / P-Glycoprotein; 0 / Piperazines; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / nutlin 3; 1N3CZ14C5O / Rhodamine 123; 5J49Q6B70F / Vincristine; EC 6.3.2.19 / Mdm2 protein, mouse; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


8. Mainguené C, Choquenet C, Cucchi JM, Dupré F, Monticelli I, Michiels JF, de Pinieux G, Vieillefond A: [Primary pleomorphic rhabdomyosarcoma of the kidney in adults: unusual tumor]. Prog Urol; 2003 Sep;13(4):679-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pleomorphic rhabdomyosarcoma of the kidney in adults: unusual tumor].
  • Primary rhabdomyosarcoma (RMS) of the kidney in an adult is a very rare and unusual tumor in this site.
  • The clinical signs associated with the flank tumoral syndrome, the histologic appearance of cytoplasmic double striation in rhabdomyoblasts and the immunohistochemical expression of skeletal muscle differentiation (desmin, myoglobin, myogenin) are described in the context of a rapidly evolving renal RMS in a 77-year old man.
  • The differential diagnosis are mainly represented by sarcomatoid renal cell carcinoma.
  • According to the neoplastic extent, the treatment includes radical nephrectomy, chemotherapy and surgery.
  • The prognosis of primary renal RMS is extremely poor, with lymph node, hepatic, bone marrow and pulmonary metastasis and a short survival rate.
  • [MeSH-major] Kidney Neoplasms / pathology. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14650305.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


9. Breitfeld PP, Lyden E, Raney RB, Teot LA, Wharam M, Lobe T, Crist WM, Maurer HM, Donaldson SS, Ruymann FB: Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol; 2001 May;23(4):225-33
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
  • PURPOSE: This study was designed to estimate the partial and complete response rates (CR and PR) of two novel drug pairs (vincristine and melphalan vs. ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma.
  • PATIENTS AND METHODS: One hundred twenty-eight patients were randomly assigned to phase II window therapy consisting of vincristine and melphalan (VM-containing regimen) or ifosfamide and etoposide (IE-containing regimen).
  • Brief window therapy (12 wks) was immediately followed-up by vincristine, dactinomycin, and cyclophosphamide (VAC), chemotherapy, surgery, and irradiation, with continuation of either VM or IE in patients with initial response.
  • Major endpoints were initial CR and PR rates after the phase II window phase of therapy, failure-free survival (FFS), and survival.
  • Also, the IE-containing regimen was associated with a gratifyingly high survival rate at 3 years (55%), which is significantly higher than has been observed on any previous Intergroup Rhabdomyosarcoma Study Group regimen for similar patients.
  • We believe that this promising outcome indicates that this drug pair merits further randomized testing in metastatic rhabdomyosarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow Diseases / chemically induced. Bronchiolitis Obliterans / chemically induced. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dactinomycin / administration & dosage. Dactinomycin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Infant. Kidney Diseases / chemically induced. Life Tables. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Neoplasm Metastasis. Radiotherapy, Adjuvant. Remission Induction. Sepsis / etiology. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Hematol Oncol. 2001 Aug-Sep;23(6):334-7 [11563765.001]
  • (PMID = 11846301.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / CA72989
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide; VAC protocol
  •  go-up   go-down


10. Ikarashi Y, Kakihara T, Imai C, Tanaka A, Watanabe A, Uchiyama M: Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children. Pediatr Int; 2004 Oct;46(5):570-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children.
  • BACKGROUND: For the purpose of studying renal side-effects induced by antineoplastic agents, the authors examined glomerular injury as well as tubular injury of patients with chemotherapy.
  • METHODS: Thirteen patients underwent a combined total of 64 courses of chemotherapy.
  • Urinary albumin, beta2-microglobulin (beta2-MG), N-acetyl-beta-glucosaminidase (NAG) and urinary protein were measured before and serially after chemotherapy.
  • RESULTS: The values of albumin/creatinine (albumin/cre) ratio and beta2-MG/creatinine (beta2-MG/cre) ratio after chemotherapy were higher than those before chemotherapy (P <0.01).
  • These were also examined before the next course of chemotherapy and were compared with those of control children.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Creatinine / urine. Kidney Tubules / drug effects. Neoplasms / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Albuminuria / etiology. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytarabine / administration & dosage. Cytarabine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Glomerular Filtration Rate / drug effects. Humans. Leukemia / drug therapy. Lymphoma / drug therapy. Methotrexate / administration & dosage. Methotrexate / adverse effects. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Proteinuria / etiology. Rhabdomyosarcoma / drug therapy. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Creatinine.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15491386.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; AYI8EX34EU / Creatinine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


11. Marina NM, Poquette CA, Cain AM, Jones D, Pratt CB, Meyer WH: Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol; 2000 Mar-Apr;22(2):112-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas.
  • PURPOSE: The aim of this study was to assess renal tubular toxicity (RTT) of ifosfamide-containing regimens (ICR) in patients with newly diagnosed sarcomas at St. Jude Children's Research Hospital.
  • Diagnoses included osteosarcoma (n = 82), Ewing sarcoma (n = 82), rhabdomyosarcoma (n = 28), and a group of other tumors (n = 7).
  • RESULTS: The authors estimated the proportion of patients with severe RTT during the first five cycles of ICR and within 1 year after therapy for three groups of patients receiving ifosfamide (IFOS, n = 110), ifosfamide/cisplatin (IFOS/CDDP, n = 51), and ifosfamide/carboplatin (IFOS/CARBO, n = 38).
  • The authors compared the probability of severe RTT among treatment groups using a generalized linear model for the first five cycles of ICR, as well as the probability of severe RTT within 1 year after therapy among treatment groups for patients receiving all prescribed IFOS using an exact chi-square test with pairwise comparisons when the three-way P value was less than 0.10.
  • Within 1 year after therapy, the proportion of patients with severe RTT differed among the three groups, and pairwise comparisons revealed a significant difference between the IFOS and the IFOS/CDDP group.
  • Severe RTT developed in four IFOS/CDDP patients more than 1 year after therapy, suggesting a long-term effect of CDDP on tubular function.
  • CONCLUSIONS: Chemotherapy regimens including IFOS/ CARBO produce severe acute RTT more frequently than regimens including IFOS or IFOS/CDDP.
  • Long-term follow-up of these patients is essential to assess whether the number of patients receiving IFOS/CDDP with severe RTT continues to increase over time and to evaluate the long-term significance of these abnormalities.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Ifosfamide / adverse effects. Kidney Tubules / drug effects. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / drug therapy. Child. Child, Preschool. Female. Humans. Infant. Male. Osteosarcoma / drug therapy. Retrospective Studies. Rhabdomyosarcoma / drug therapy. Sarcoma, Ewing / drug therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10779023.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765; United States / NCI NIH HHS / CA / P30 CA 23099
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Modak S, Guo HF, Humm JL, Smith-Jones PM, Larson SM, Cheung NK: Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm; 2005 Oct;20(5):534-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9.
  • Although metastatic rhabdomyosarcoma (RMS) is chemotherapy and radiotherapy responsive, few patients are cured.
  • Mean tumor: tissue ratios were maximal at 172 hours (for lung, 4, kidney, 6, liver, 7, spleen, 11, femur, 14, muscle, 18, and brain, 48).
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Carcinoma, Small Cell / therapy. Lung Neoplasms / therapy. Radioimmunotherapy / methods. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Epithelium / metabolism. Female. Humans. Immunoglobulin G / chemistry. Immunohistochemistry. Iodine Radioisotopes / therapeutic use. Kinetics. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Neoplasm Transplantation. Protein Binding. Time Factors. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16248769.001).
  • [ISSN] 1084-9785
  • [Journal-full-title] Cancer biotherapy & radiopharmaceuticals
  • [ISO-abbreviation] Cancer Biother. Radiopharm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 8H9 monoclonal antibody; 0 / Antibodies, Monoclonal; 0 / Immunoglobulin G; 0 / Iodine Radioisotopes
  •  go-up   go-down


13. Sola JE, Cova D, Casillas J, Alvarez OA, Qualman S, Rodriguez MM: Primary renal botryoid rhabdomyosarcoma: diagnosis and outcome. J Pediatr Surg; 2007 Dec;42(12):e17-20
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for botryoid rhabdomyosarcoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary renal botryoid rhabdomyosarcoma: diagnosis and outcome.
  • Primary renal rhabdomyosarcoma is a rare entity.
  • We report on a pediatric patient who, despite having multiple metastases to the lung on presentation, is free of disease 28 months after radical nephrectomy combined with chemotherapy and radiation therapy.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Child, Preschool. Combined Modality Therapy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Nephrectomy / methods. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18082685.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


14. Iankelevich MIa, Dolgopolov IS, Andreeva LIu, Ravshanova RS, Izhogin DG, Mkheidze DM, Ogorodnikova EV, Mentkevich GL: [Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children]. Vestn Ross Akad Med Nauk; 2000;(6):21-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of subgrafting doses of peripheral stem cells is a new approach to overcoming hematological toxicity of multiple intensive courses of chemotherapy in children].
  • The authors examined 8 patients with pretreated relapsing or resistant solid tumors (Wilms'--4, rhabdomyosarcoma--3, synovial sarcoma--1) who received 16 courses of chemotherapy: iphosphamide, 1800 mg/m2/day (days 1-5), vepeside, 100 mg/m2/day (days 1-5), and carboplatin 500 mg/m2/day (day 1) (IVC) and 18 courses of therapy wherein iphosphamide was replaced by cyclophosphanum, 400 mg/m2/day (days 1-5) (CVC).
  • The findings suggest that the small doses of PSC stimulated by colony-stimulating factor can maintain hemopoiesis and decrease the rate of the estimated bone marrow depletion long after repeated courses of chemotherapy in patients with prognostically poor solid tumors.

  • MedlinePlus Health Information. consumer health - Blood Disorders.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10943156.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Cajaiba MM, Bale AE, Alvarez-Franco M, McNamara J, Reyes-Múgica M: Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome. Nat Clin Pract Oncol; 2006 Oct;3(10):575-80
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma, Wilms tumor, and deletion of the patched gene in Gorlin syndrome.
  • During ultrasound investigation, a left renal mass was also detected.
  • The patient underwent surgical removal of both neoplasms, which were diagnosed as a rhabdomyosarcoma and a Wilms tumor.
  • DIAGNOSIS: Gorlin syndrome with synchronous rhabdomyosarcoma and Wilms tumor.
  • MANAGEMENT: Left nephrectomy, excision of paravesical tumor, excision of mandibular cysts, chemotherapy, and radiotherapy.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Kidney Neoplasms / surgery. Rhabdomyosarcoma / surgery. Wilms Tumor / surgery

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019435.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / patched receptors
  •  go-up   go-down


16. Kunieda K, Saji S, Kuwabara I, Watanabe A, Katoh M, Sugiyama Y, Shimokawa K: Rapid growth of a retroperitoneal rhabdomyosarcoma following right hemicolectomy for ascending colon cancer: report of a case. Surg Today; 2000;30(4):372-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of a retroperitoneal rhabdomyosarcoma following right hemicolectomy for ascending colon cancer: report of a case.
  • We report herein the case of a 69-year-old man in whom rapid growth of a retroperitoneal rhabdomyosarcoma occurred following hemicolectomy for ascending colon cancer.
  • On his first admission for surgery, a small lesion, 1.5 cm in diameter, was detected adjacent to the inner side of the left kidney by abdominal axial computed tomography (CT), which was initially suspected to be a benign lesion; however, a postoperative follow-up CT scan done 5 months later revealed that the lesion had enlarged remarkably to 8 cm in diameter.
  • Thus, total resection was performed under the presumed diagnosis of a malignant retroperitoneal tumor.
  • The tumor was found to be adjacent to the inner portion of the left kidney and covered by Gerota's fascia.
  • The resected specimen was 8.5 x 6.5 x 5 cm in size and was histologically confirmed as a retroperitoneal rhabdomyosarcoma of embryonal type.
  • Two courses of adjuvant chemotherapy with adriamycin, vincristine, and cyclophosphamide were given, and the patient has shown no signs of recurrence for 2 years since his second operation.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy. Colonic Neoplasms / surgery. Neoplasms, Second Primary. Retroperitoneal Neoplasms / pathology. Rhabdomyosarcoma, Embryonal / pathology
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10795872.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  •  go-up   go-down


17. Davidson A, Dick G, Pritchard-Jones K, Pinkerton R: EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. Eur J Cancer; 2002 Dec;38(18):2422-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation.
  • Tumour types were neuroblastoma 3, Ewing's sarcoma 2, rhabdomyosarcoma 5, osteosarcoma 3, desmoplastic small round cell tumour 1, nephroblastoma 1, T-acute lymphoblastic leukaemia (ALL) 1.
  • All had progressed or relapsed following at least two of the drug types included in EVE.
  • Renal and hepatic toxicity was rarely severe and always transient.
  • Partial responses (PR) were observed in 2 patients (1 rhabdomyosarcoma, 1 Ewing's sarcoma).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclosporine / administration & dosage. Cyclosporine / adverse effects. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Epirubicin / administration & dosage. Epirubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Gastrointestinal Diseases / chemically induced. Heart Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Kidney Diseases / chemically induced. Male. Vincristine / administration & dosage. Vincristine / adverse effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2002 Dec;38(18):2337-40 [12460776.001]
  • (PMID = 12460787.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


18. Kremens B: [Systemic therapy in children and adolescents]. Urologe A; 2007 Oct;46(10):1404-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic therapy in children and adolescents].
  • Urologic malignancies in childhood and adolescence are mainly nephroblastomas, neuroblastomas, soft tissue sarcomas, and germ cell tumors.
  • National and supranational treatment studies are the standard of care for pediatric cancer in Germany; they yield 5-year survival rates of almost 90% for nephroblastoma and germ cell tumors and 60% for neuroblastoma (all stages) and rhabdomyosarcoma.
  • The principles of antineoplastic therapy are the same as in adult cancer medicine; the drugs used depend upon the disease.
  • In a multimodal treatment strategy, the role of chemotherapy as well as that of surgery and radiotherapy can differ, as is described for nephroblastoma, infant neuroblastoma, and stage 4 neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Urogenital Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adrenal Gland Neoplasms / drug therapy. Adrenal Gland Neoplasms / mortality. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adrenal Medulla. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Humans. Infant. Kidney Neoplasms / drug therapy. Kidney Neoplasms / mortality. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / drug therapy. Neoplasms, Germ Cell and Embryonal / mortality. Neoplasms, Germ Cell and Embryonal / pathology. Neoplasms, Germ Cell and Embryonal / surgery. Neuroblastoma / drug therapy. Neuroblastoma / mortality. Neuroblastoma / pathology. Neuroblastoma / surgery. Prognosis. Radiotherapy, Adjuvant. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / surgery. Survival Rate. Wilms Tumor / drug therapy. Wilms Tumor / mortality. Wilms Tumor / pathology. Wilms Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823786.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Most patients received chemotherapy in addition to bevacizumab.
  • Duration of bevacizumab therapy ranged from 1.5 to 23 months.
  • Radiographic objective responses (partial responses) were observed in two patients with astrocytoma grade III and in one patient each with neuroblastoma and pleomorphic rhabdomyosarcoma, respectively.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


20. Merguerian PA, Chang B: Pediatric genitourinary tumors. Curr Opin Oncol; 2002 May;14(3):273-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each year advances are made in the clinical evaluation and treatment of genitourinary tumors in children.
  • In addition, information is accumulating about the long-term outcome and complications associated with treatment modalities.
  • This article reviews the 2001 literature on pediatric Wilms tumor, other renal tumors, rhabdomyosarcoma of the pelvis, paratesticular rhabdomyosarcoma, and testicular tumors.
  • Long-term complications of treatment are also discussed, including short stature and leukemia.
  • The Intergroup Rhabdomyosarcoma Study Group reported on the results of treatment for nonmetastatic disease and the goals of the upcoming Study V, reduction of chemotherapy and radiotherapy.
  • [MeSH-minor] Child. Clinical Trials as Topic. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Male. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Testicular Neoplasms / diagnosis. Testicular Neoplasms / pathology. Testicular Neoplasms / therapy. Treatment Outcome. Wilms Tumor / diagnosis. Wilms Tumor / pathology. Wilms Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981271.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


21. Castellino SM, McLean TW: Pediatric genitourinary tumors. Curr Opin Oncol; 2007 May;19(3):248-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Survival continues to improve for primary renal, bladder/prostate and testicular tumors in childhood.
  • The addition of more intensive chemotherapy for anaplastic histology disease, recognition of loss of heterozygosity for chromosomes 1p and 16q as an adverse prognostic factor in favorable histology Wilms' tumor, and the utilization of molecular markers to better characterize all renal tumors will better enable individualized therapy.
  • Recognition and treatment of anaplastic histology and bilateral Wilms' tumor remains a challenge.
  • In rhabdomyosarcoma, genitourinary site and embryonal histology confer a relatively favorable prognosis.
  • SUMMARY: Advances in molecular oncology, diagnostic imaging, surgical approaches and long-term follow-up of childhood cancer survivors drive risk-stratified therapy in pediatric genitourinary tumors.
  • [MeSH-major] Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / therapy
  • [MeSH-minor] Child. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Loss of Heterozygosity. Male. Neoplasm Staging. Prognosis. Rhabdomyosarcoma / genetics. Rhabdomyosarcoma / metabolism. Wilms Tumor / diagnosis. Wilms Tumor / genetics. Wilms Tumor / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414644.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 66
  •  go-up   go-down


22. Estlin EJ, Veal GJ: Clinical and cellular pharmacology in relation to solid tumours of childhood. Cancer Treat Rev; 2003 Aug;29(4):253-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our understanding of the clinical and cellular pharmacology of drugs commonly used in the treatment of childhood cancer have increased greatly over the past two decades.
  • Recent pre-clinical and clinical evaluation of the topoisomerase I inhibitors topotecan and irinotecan has highlighted the potential importance of pharmacological factors in their effectiveness as cytotoxics.
  • For each disease type, knowledge of the clinical and cellular pharmacology of a candidate drug will be related to pharmacodynamic responses such as response, toxicity and prognosis.
  • For diseases such as Wilms' tumour, osteogenic sarcoma and Ewing's tumour, histological response to initial induction chemotherapy is of prognostic significance, and the depth of response is increasingly recognised as an important determinant of prognosis for high-risk neuroblastoma.
  • For several of these tumour types, the dose-intensity of chemotherapy may be an important variable in determining prognosis.
  • However the relationship between pharmacokinetic variability, cellular pharmacology and the major determinants of chemosensitivity to those drugs employed in first line therapy is unknown.
  • Indeed, the optimisation of current therapies may be required to allow a fully informed selection of those children for whom novel therapies are truly needed.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Bone Neoplasms / drug therapy. Child. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Enzyme Inhibitors / therapeutic use. Humans. Kidney Neoplasms / drug therapy. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Topoisomerase I Inhibitors. Wilms Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12927566.001).
  • [ISSN] 0305-7372
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Topoisomerase I Inhibitors
  • [Number-of-references] 191
  •  go-up   go-down


23. Abhyankar A, Jenney M, Huddart SN, Tilsley DW, Cox R, Saad M: Use of a tissue expander and a polyglactic acid (Vicryl) mesh to reduce radiation enteritis: case report and literature review. Pediatr Surg Int; 2005 Sep;21(9):755-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a tissue expander and a polyglactic acid (Vicryl) mesh to reduce radiation enteritis: case report and literature review.
  • Management of stage IV rhabdomyosarcoma comprises systemic chemotherapy with local control by conservative surgery and radiotherapy.
  • We report a case of metastatic alveolar rhabdomyosarcoma requiring radiotherapy to the right renal bed.
  • Effective displacement of small bowel from the tumour site was achieved by a combined use of a tissue expander and Vicryl mesh.
  • This is the first report discussing combined use of a tissue expander and Vicryl mesh to aid radiotherapy to the renal fossa in a paediatric patient.
  • [MeSH-major] Enteritis / surgery. Intestine, Small / radiation effects. Polyglactin 910. Prosthesis Implantation / instrumentation. Radiation Injuries / surgery. Surgical Mesh. Tissue Expansion Devices
  • [MeSH-minor] Biopsy. Child. Follow-Up Studies. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / secondary. Male. Mediastinal Neoplasms / diagnostic imaging. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / radiotherapy. Rhabdomyosarcoma, Alveolar / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 2000 Sep;70(9):690-2 [10976905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):568-72 [7749532.001]
  • [Cites] Dis Colon Rectum. 1991 Sep;34(9):833-5 [1914752.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):438-43 [11104616.001]
  • [Cites] Dis Colon Rectum. 1992 Sep;35(9):897-901 [1387358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1565-73 [3759581.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):269-71 [6612575.001]
  • [Cites] Ann Chir. 1996;50(1):58-71 [8734278.001]
  • [Cites] Am Surg. 1994 Jul;60(7):473-82; discussion 482-3 [8010560.001]
  • [Cites] Dig Dis Sci. 1996 Feb;41(2):392-401 [8601388.001]
  • [Cites] Bull Cancer. 1989;76(10):1121-5 [2635639.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):469-76 [2394624.001]
  • [Cites] Br J Radiol. 1993 Jan;66(781):67-73 [8428254.001]
  • [Cites] Br J Surg. 1987 Aug;74(8):742-7 [3307993.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • (PMID = 16133520.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 34346-01-5 / Polyglactin 910
  •  go-up   go-down


24. Lamalmi N, Rouas L, Cherradi N, Malihy A, Khattab M, Alhamany Z: [Botryoid Wilms tumor extending into the duodenum]. Arch Pediatr; 2010 Dec;17(12):1664-6
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This uncommon macroscopic form of nephroblastoma consists entirely of a polypoid renal intrapelvic mass.
  • The main differential diagnosis of this unusual tumor is botryoid rhabdomyosarcoma.
  • Radiology revealed a large heterogeneous mass in the renal calyx, protruding into the ureter.
  • The pathologic diagnosis was mixed type nephroblastoma, SIOP 2001 stage III.
  • The patient was given a course of postoperative chemotherapy.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ureteral Neoplasms / diagnosis. Wilms Tumor / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant / methods. Diagnosis, Differential. Humans. Infant. Male. Neoplasm Invasiveness. Neoplasm Staging. Nephrectomy. Rhabdomyosarcoma / diagnosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20943355.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


25. Carli M, Passone E, Perilongo G, Bisogno G: Ifosfamide in pediatric solid tumors. Oncology; 2003;65 Suppl 2:99-104
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma.
  • Furthermore, an increase in tumor response rate has been observed when ifosfamide has been used in combination with other drugs.
  • Some controversies still exist on the modality of drug administration and more precisely on the time of infusion, however in pediatric practice, short infusion (e.g.
  • Ifosfamide is currently included in the standard therapy of pediatric bone and soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Ifosfamide / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Bone Neoplasms / drug therapy. Child. Cyclophosphamide / therapeutic use. Germinoma / drug therapy. Humans. Kidney Neoplasms / drug therapy. Neuroblastoma / drug therapy. Osteosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Wilms Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 14586158.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 38
  •  go-up   go-down


26. D'Antiga L, Baker A, Pritchard J, Pryor D, Mieli-Vergani G: Veno-occlusive disease with multi-organ involvement following actinomycin-D. Eur J Cancer; 2001 Jun;37(9):1141-8
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between 1993 and 1998, we managed 6 patients, all male, median age 19 months (range 6-48 months) who received Act-D for Wilms' tumour (n=4), clear cell sarcoma (n=1) or rhabdomyosarcoma (n=1).
  • All six children developed encephalopathy, hepatomegaly, ascites, reversed portal flow and renal impairment.
  • The treatment was supportive.
  • Severe Adult Respiratory Distress Syndrome developed in 3 patients, all of whom died.
  • Intravascular coagulopathy precedes and characterises severe VOD during Act-D treatment.
  • [MeSH-minor] Child, Preschool. Constriction, Pathologic. Humans. Infant. Kidney Neoplasms / drug therapy. Male. Rhabdomyosarcoma / drug therapy. Testicular Neoplasms / drug therapy. Wilms Tumor / drug therapy

  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11378345.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 1CC1JFE158 / Dactinomycin
  •  go-up   go-down


27. Jagadeeswaran R, Thirunavukkarasu C, Gunasekaran P, Ramamurty N, Sakthisekaran D: In vitro studies on the selective cytotoxic effect of crocetin and quercetin. Fitoterapia; 2000 Aug;71(4):395-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Crocetin (5-20 microg/ml), quercetin (10-40 microg/ml), and cisplatin (60-180 microg/ml) used as a positive control drug, were tested against human rhabdomyosarcoma (RD) cells and African green monkey kidney (Vero) cells.
  • Morphological observation by phase contrast microscopy revealed that both crocetin and quercetin caused intense damage only on the malignant (RD) cells, whereas mild toxic effect was seen with cisplatin also on normal (Vero) cells.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Carotenoids / pharmacology. Quercetin / pharmacology. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cercopithecus aethiops. Cisplatin / pharmacology. Dose-Response Relationship, Drug. Humans. L-Lactate Dehydrogenase / drug effects. Tumor Cells, Cultured / drug effects

  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10925010.001).
  • [ISSN] 0367-326X
  • [Journal-full-title] Fitoterapia
  • [ISO-abbreviation] Fitoterapia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 20TC155L9C / crocetin; 36-88-4 / Carotenoids; 9IKM0I5T1E / Quercetin; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


28. Meco D, Colombo T, Ubezio P, Zucchetti M, Zaffaroni M, Riccardi A, Faircloth G, Jose J, D'Incalci M, Riccardi R: Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol; 2003 Aug;52(2):131-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To investigate the cytotoxic and antitumor effects of the combination of the novel anticancer drug ET-743 and doxorubicin (Dx) and to determine whether any pharmacokinetic interaction occurs in sarcoma-bearing mice.
  • METHODS: The cytotoxicity of each drug and of their combinations was assessed in the rhabdomyosarcoma cell line TE-671 by a clonogenic assay, and isobologram analysis was performed to detect any synergistic, additive or antagonistic effects.
  • The antitumor activities of each drug and of the combinations were also evaluated in nude mice transplanted subcutaneously with human TE-671 rhabdomyosarcoma and in C3H female mice injected intravenously with UV2237 M fibrosarcoma or with the Dx-resistant subline UV2237 M-ADM which overexpresses Pgp.
  • Antitumor activity was evaluated by monitoring the TE-671 tumor volume over time and, in the case of the murine fibrosarcomas, by evaluation of lung deposits at autopsy quantified by determining lung weight.
  • ET-743 was determined in plasma by an HPLC-MS method and Dx in plasma and tissue by an HPLC method with fluorescence detection.
  • Giving ET-743 1 h before Dx slightly enhanced the effect (LCK 1.12) compared with giving the drugs simultaneously (LCK 0.85) or in the opposite sequence (LCK 0.92).
  • In UV2237 M fibrosarcoma, both Dx and ET-743 showed an effect in reducing the weight of lung metastases, although the combination of the two drugs was not superior to each drug alone.
  • In UV2237 M-ADM tumors neither of the two drugs was active, whereas the combination, particularly when the two drugs were given simultaneously, produced a significant effect.
  • Plasma levels of ET-743 and Dx were not significantly different when the drugs were given alone or in combination.
  • The concentrations of Dx in tissues including tumor, liver, heart and kidney were found to be the same whether the drug was given alone or in combination with ET-743.
  • In mice no pharmacokinetic interaction between the two drugs was found.
  • The observed activity in UV2237 M-ADM and in human TE-671 sarcoma suggests that the combination of the two drugs could be effective for tumors displaying low sensitivity to each drug given alone.
  • Based on these findings a phase I study on the combination of the two drugs was recently initiated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / drug therapy
  • [MeSH-minor] Animals. Cell Survival / drug effects. Dioxoles / administration & dosage. Dioxoles / pharmacology. Doxorubicin / administration & dosage. Doxorubicin / pharmacology. Drug Screening Assays, Antitumor. Drug Synergism. Female. Humans. Inhibitory Concentration 50. Isoquinolines / administration & dosage. Isoquinolines / pharmacology. Mice. Mice, Inbred C3H. Mice, Nude. Neoplasm Transplantation. Tetrahydroisoquinolines. Tissue Distribution. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12783202.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin; 80168379AG / Doxorubicin
  •  go-up   go-down


29. Herrera JM, Krebs A, Harris P, Barriga F: Childhood tumors. Surg Clin North Am; 2000 Apr;80(2):747-60, xii
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific genetic anomalies with pathogenic significance, which have helped to define the diagnosis better and to improve the prognosis of children with these tumors, recently have been discovered.
  • Survival of children with solid tumors also has improved significantly because of effective multidisciplinary care, which, in this case, always involves chemotherapy and surgery.
  • Diagnostic and therapeutic principles for the most common childhood solid tumors are discussed in this article, with an emphasis on surgical procedures.
  • [MeSH-minor] Adolescent. Bone Neoplasms / surgery. Child. Hepatoblastoma / therapy. Humans. Kidney Neoplasms / surgery. Liver Neoplasms / therapy. Neoplasm Staging. Neuroblastoma / therapy. Osteosarcoma / surgery. Patient Care Team. Rhabdomyosarcoma / therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10836015.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 98
  •  go-up   go-down


30. Notteghem P, Soler C, Dellatolas G, Kieffer-Renaux V, Valteau-Couanet D, Raimondo G, Hartmann O: Neuropsychological outcome in long-term survivors of a childhood extracranial solid tumor who have undergone autologous bone marrow transplantation. Bone Marrow Transplant; 2003 Apr;31(7):599-606
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total, 76 children treated for an extracranial tumor with BMT without total body irradiation (TBI) were evaluated at least 5 years after the end of the treatment.Overall, their performance and skills were in the normal range and their professional and academic outcomes were satisfactory.
  • Nevertheless, we observed a deleterious effect of deafness on verbal IQ associated with the previous administration of cisplatin during conventional chemotherapy.
  • [MeSH-major] Bone Marrow Transplantation / psychology. Nervous System Neoplasms / psychology. Nervous System Neoplasms / therapy. Neuroblastoma / psychology. Neuroblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / psychology. Bone Neoplasms / therapy. Child. Dyslexia, Acquired. Educational Status. Endodermal Sinus Tumor / psychology. Endodermal Sinus Tumor / therapy. Female. Hearing Loss, Sensorineural. Humans. Kidney Neoplasms / psychology. Kidney Neoplasms / therapy. Lymphoma / psychology. Lymphoma / therapy. Male. Memory. Neuropsychological Tests. Osteosarcoma / psychology. Osteosarcoma / therapy. Rhabdomyosarcoma / psychology. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / psychology. Sarcoma, Ewing / therapy. Sick Leave. Transplantation, Autologous. Wilms Tumor / psychology. Wilms Tumor / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12692628.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F: Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol; 2009 Nov 10;27(32):5350-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is aimed at evaluating the incidence of late renal toxicity of ifosfamide and its risk factors.
  • PATIENTS AND METHODS: Of the 183 patients prospectively investigated for renal function, 77 treated for rhabdomyosarcoma, 39 for other soft tissue sarcoma, 39 for Ewing's sarcoma, and 28 for osteosarcoma were investigated at least 5 years after treatment.
  • Ifosfamide dose and interval from therapy to investigations were predictors of tubulopathy in univariate and multivariate analysis.
  • In a multivariate analysis, an older age at diagnosis and the length of interval since treatment had independent impacts on the risk of abnormal GFR.
  • CONCLUSION: Renal toxicity is moderate with a moderate dose of ifosfamide.
  • However, since it can be permanent and can get worse with time, repeated long-term evaluations are important, and this risk should be balanced against efficacy.
  • [MeSH-major] Ifosfamide / adverse effects. Kidney / drug effects. Kidney Diseases / chemically induced
  • [MeSH-minor] Antineoplastic Agents, Alkylating / adverse effects. Antineoplastic Agents, Alkylating / therapeutic use. Child. Follow-Up Studies. Humans. Kidney Function Tests. Multivariate Analysis. Osteosarcoma / drug therapy. Prospective Studies. Regression Analysis. Rhabdomyosarcoma / drug therapy. Risk Factors. Sarcoma / drug therapy. Sarcoma, Ewing / drug therapy. Time Factors

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19826134.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


32. Sparano A, Kreiger P, Kazahaya K: Malignant rhabdoid tumor of the parapharyngeal space. Ear Nose Throat J; 2009 Mar;88(3):E24-6
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant rhabdoid tumor of the parapharyngeal space.
  • Malignant rhabdoid tumor has been a somewhat controversial entity since it was first described in 1978 as a possible sarcomatous variant of Wilms tumor.
  • Eventually, however, it was found to be a distinct neoplastic tumor with histologic characteristics similar to those of rhabdomyosarcoma.
  • Malignant rhabdoid tumors affect children.
  • Clinically, they occur primarily in the kidney, and they behave aggressively.
  • Associated mortality is significant, even with combined-modality treatment regimens.
  • We describe the case of a large extrarenal malignant rhabdoid tumor of the parapharyngeal space with extension to the infratemporal fossa and skull base in a previously healthy 2-year-old girl who had presented with a cervical mass and ipsilateral Horner syndrome.
  • The patient underwent complete surgical extirpation of the lesion and received adjunctive cisplatin chemotherapy and radiation therapy, and she remained disease-free at 9 months of follow-up.
  • Given the age group of the patients that these neoplasms most commonly affect and given the neoplasms' resemblance to rhabdomyosarcoma and other small round-cell tumors of the head and neck, discussion of the associated clinical pathology, imaging characteristics, histopathologic features, and mode of management are of particular importance, especially so in view of the uncommon location of the tumor in this specific case.
  • Such a discussion may help lead to minimization of misdiagnosis and maximization of therapeutic benefit.
  • [MeSH-minor] Child, Preschool. Female. Humans. Necrosis / pathology. Voice Disorders / diagnosis. Voice Disorders / etiology

  • Genetic Alliance. consumer health - Rhabdoid tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19291622.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ: SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer; 2008 Mar;50(3):703-6
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rh1, which was previously categorized as an alveolar rhabdomyosarcoma cell line, also has a gene expression profile suggestive of Ewing sarcoma and expresses EWS-FLI1 fusion transcripts in which exon 7 of EWS is joined with exon 6 of FLI1.
  • [MeSH-major] Cell Line, Tumor. Kidney Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Sarcoma, Ewing / pathology. Wilms Tumor / pathology
  • [MeSH-minor] Adult. Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Diagnostic Errors. Drug Screening Assays, Antitumor. Female. Gene Expression Profiling. Humans. Male. Mice. Oncogene Proteins, Fusion / analysis. Oncogene Proteins, Fusion / genetics. Pleural Effusion, Malignant / pathology. Proto-Oncogene Protein c-fli-1. RNA-Binding Protein EWS. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / analysis. Transcription Factors / genetics. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17154184.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down


34. Morton CL, Favours EG, Mercer KS, Boltz CR, Crumpton JC, Tucker C, Billups CA, Houghton PJ: Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs; 2007 Aug;25(4):285-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: ABT-751 was evaluated against 27 subcutaneously implanted xenograft models of childhood cancer including neuroblastoma [4], osteosarcoma [4], Ewing sarcoma [2] rhabdomyosarcoma [8], medulloblastoma [1] and eight kidney cancer lines (six Wilms tumors, two rhabdoid).
  • (2) treated to control (T/C) tumor volume at day 21; and (3) a time to event measure based on the median event free survival (EFS) of treated and control lines.
  • Other regressions occurred in rhabdomyosarcoma and Wilms tumor models.
  • Neuroblastoma models appear somewhat more sensitive to this agent, with objective regressions also in rhabdomyosarcoma and Wilms tumor.
  • [MeSH-major] Antimitotic Agents / therapeutic use. Neoplasms, Experimental / drug therapy. Sulfonamides / therapeutic use

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6615-24 [16166440.001]
  • [Cites] Cancer Res. 1997 Aug 1;57(15):3208-13 [9242451.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):837-44 [15120039.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):725-32 [16967299.001]
  • [Cites] Invest New Drugs. 1996;14(1):37-47 [8880392.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81 [15173957.001]
  • [Cites] Bioorg Med Chem Lett. 2001 Jul 9;11(13):1671-3 [11425534.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Cancer Chemother Pharmacol. 2001;47(2):179-84 [11269745.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3646-57 [12473573.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4882-7 [16914576.001]
  • [Cites] Int J Cancer. 1995 Sep 27;63(1):119-23 [7558438.001]
  • [Cites] Br J Cancer Suppl. 1996 Jul;27:S86-8 [8763854.001]
  • [Cites] Clin Cancer Res. 2006 May 1;12(9):2834-40 [16675578.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1702-6 [8137285.001]
  • [Cites] Anticancer Drugs. 1997 Apr;8(4):313-22 [9180383.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4039-47 [15961757.001]
  • [Cites] Eur J Cancer. 1991;27(4):482-7 [1827725.001]
  • [Cites] Adv Exp Med Biol. 1994;345:417-22 [8079737.001]
  • [Cites] Jpn J Cancer Res. 1998 Sep;89(9):954-62 [9818032.001]
  • [Cites] Pediatr Blood Cancer. 2008 Mar;50(3):703-6 [17154184.001]
  • [Cites] J Clin Oncol. 1999 Jun;17 (6):1815-24 [10561220.001]
  • (PMID = 17384918.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / CA23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT751; 0 / Antimitotic Agents; 0 / Sulfonamides
  •  go-up   go-down


35. Lowichik A, Zhou H, Pysher TJ, Smith L, Lemons R, Coffin CM: Therapy associated changes in childhood tumors. Adv Anat Pathol; 2000 Nov;7(6):341-59
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy associated changes in childhood tumors.
  • Contemporary treatment regimens for the common solid tumors of childhood have led to increased numbers of post-treatment pathologic specimens from survivors.
  • Current therapeutic strategies for childhood cancers in North America require an accurate pathologic diagnosis and stratify patients based on combinations of clinical, biological, and pathologic features.
  • In several tumor systems, the pathologic response to therapy also modifies the treatment regimen.
  • Accurate pathologic interpretation of such specimens is critical in providing useful prognostic information for therapeutic decisions.
  • Standardized handling of post-therapy pathologic specimens, appropriate use of molecular and genetic studies, consideration of the differential diagnoses, and assessment of the potential biologic significance of therapy-induced pathologic changes are, therefore, critical for patient management and determination of treatment protocols.
  • [MeSH-minor] Adolescent. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Child. Child, Preschool. Fibrosarcoma / pathology. Fibrosarcoma / therapy. Hepatoblastoma / pathology. Hepatoblastoma / therapy. Histocytochemistry. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Kidney Neoplasms / surgery. Liver Neoplasms / pathology. Liver Neoplasms / therapy. Neuroectodermal Tumors, Primitive, Peripheral / drug therapy. Neuroectodermal Tumors, Primitive, Peripheral / pathology. Osteosarcoma / pathology. Osteosarcoma / surgery. Prognosis. Rhabdomyosarcoma / drug therapy. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / surgery. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Wilms Tumor / drug therapy. Wilms Tumor / pathology. Wilms Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11078058.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 149
  •  go-up   go-down


36. Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R: Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol; 2002 Oct;17(10):825-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present three patients who experienced nephrotoxicity and prolonged exposure to toxic MTX concentrations following high-dose infusions during treatment for osteogenic sarcomas.
  • We review the literature and discuss guidelines for early and aggressive treatment for this complication of high-dose MTX therapy.
  • Clinically important removal of MTX depends upon prompt initiation of HD after detection of nephrotoxicity and delayed clearance of MTX.
  • Therapy is indicated in cases where compassionate use of CPDG(2) may not be available, or while awaiting its delivery.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / blood. Kidney Diseases / chemically induced. Kidney Diseases / therapy. Methotrexate / adverse effects. Methotrexate / blood. Renal Dialysis
  • [MeSH-minor] Adolescent. Bone Neoplasms / drug therapy. Female. Fluorescence Polarization Immunoassay. Half-Life. Humans. Hypokalemia / etiology. Hypophosphatemia / etiology. Infusions, Intravenous. Male. Osteosarcoma / drug therapy. Rhabdomyosarcoma / drug therapy. gamma-Glutamyl Hydrolase / therapeutic use

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12376811.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


37. van Dalen EC, Raphaël MF, Caron HN, Kremer LC: Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer. Cochrane Database Syst Rev; 2009;(1):CD006647
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
  • A well-informed decision on the use of anthracyclines in the treatment of different types of childhood cancer should be based on the available evidence on both antitumour efficacy and cardiotoxicity.
  • OBJECTIVES: To compare antitumour efficacy of treatment including or not including anthracyclines in children with childhood cancer.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) comparing treatment of any type of childhood cancer with and without anthracyclines and reporting outcomes concerning antitumour efficacy.
  • MAIN RESULTS: We identified RCTs for 5 types of tumour: acute lymphoblastic leukaemia (ALL) (n=3; 912 children), Wilms' tumour (n=1; 316 children), rhabdomyosarcoma/undifferentiated sarcoma (n=1; 413 children), Ewing's sarcoma (n=1; 94 children), and non-Hodgkin lymphoma (n=1; 284 children).
  • For both Wilms' tumour and Ewing's sarcoma a significant difference in survival in favour of treatment with anthracyclines was identified.
  • For both rhabdomyosarcoma/undifferentiated sarcoma and non-Hodgkin lymphoma no difference in antitumour efficacy between the treatment groups was identified.
  • No significant difference between both treatment groups was identified, but in all individual studies there was a suggestion of a lower rate of clinical cardiotoxicity in patients who did not receive anthracyclines.
  • For Wilms' tumour, rhabdomyosarcoma/undifferentiated sarcoma, Ewing's sarcoma, and non-Hodgkin lymphoma only 1 RCT was available and therefore, no definitive conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours.
  • For other childhood cancers no RCTs were identified and therefore, no conclusions can be made about the antitumour efficacy of treatment with or without anthracyclines in these tumours.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Neoplasms / drug therapy
  • [MeSH-minor] Bone Neoplasms / drug therapy. Child. Heart Diseases / chemically induced. Humans. Kidney Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Randomized Controlled Trials as Topic. Sarcoma / drug therapy. Wilms Tumor / drug therapy

  • Genetic Alliance. consumer health - Childhood Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2011;(1):CD006647 [21249679.001]
  • (PMID = 19160293.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antibiotics, Antineoplastic
  • [Number-of-references] 172
  •  go-up   go-down






Advertisement